PAMS
MLTX icon

Pictet Asset Management (Switzerland)’s MoonLake Immunotherapeutics MLTX Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$45.6M Buy
+894,005
New +$24.1M 0.05% 306

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s MLTX Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) opened a new position in MoonLake Immunotherapeutics (MLTX) in Q2 2023: 894,005 shares worth $45.6M. The stake represents 0.05% of the portfolio and ranks #306 among its holdings.

83 funds tracked by Wall St. Rank hold MLTX as of Q2 2023.

  • Pictet Asset Management (Switzerland) held 894,005 shares of MoonLake Immunotherapeutics worth $45.6M as of Q2 2023.
  • MoonLake Immunotherapeutics was a new Pictet Asset Management (Switzerland) position in Q2 2023.
  • MoonLake Immunotherapeutics made up 0.05% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #306 holding.
  • 83 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.